I'm LongbridgeAI, I can summarize articles.The latest update is out from Tianda Pharmaceuticals Ltd. ( (HK:0455) ).
Tianda Pharmaceuticals reported interim revenue of HK$164.2 million for the six months ended 30 June 2026, up from HK$136.6 million a year earlier, driven by higher sales despite increased cost of sales and operating expenses. The company’s gross profit rose to HK$66.1 million, but the group still recorded a net loss of HK$32.2 million and a total comprehensive loss of HK$15.2 million, reflecting ongoing pressures on profitability even as top-line performance improved.
Selling, distribution and administrative expenses continued to weigh on the bottom line, alongside finance costs, though research and development spending declined versus the prior period. Currency movements provided some offset through exchange gains in other comprehensive income, slightly narrowing the overall comprehensive loss and highlighting the group’s exposure to foreign exchange swings in its geographically diversified operations.
More about Tianda Pharmaceuticals Ltd.
Tianda Pharmaceuticals Limited is a Hong Kong-listed pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical products. The group focuses on healthcare solutions and operates through various subsidiaries, with a presence in mainland China and international markets.
Average Trading Volume: 142,193
Technical Sentiment Signal: Sell
Current Market Cap: HK$221.5M
